Logo image of NPCE

NEUROPACE INC (NPCE) Stock Fundamental Analysis

NASDAQ:NPCE - Nasdaq - US6412881053 - Common Stock - Currency: USD

13.31  +0.42 (+3.26%)

Fundamental Rating

3

NPCE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of NPCE have multiple concerns. NPCE is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NPCE has reported negative net income.
In the past year NPCE has reported a negative cash flow from operations.
NPCE had negative earnings in each of the past 5 years.
NPCE had a negative operating cash flow in each of the past 5 years.
NPCE Yearly Net Income VS EBIT VS OCF VS FCFNPCE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of NPCE (-28.68%) is comparable to the rest of the industry.
The Return On Equity of NPCE (-338.71%) is worse than 82.54% of its industry peers.
Industry RankSector Rank
ROA -28.68%
ROE -338.71%
ROIC N/A
ROA(3y)-33.52%
ROA(5y)-34.1%
ROE(3y)-211.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NPCE Yearly ROA, ROE, ROICNPCE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

NPCE has a better Gross Margin (73.94%) than 85.19% of its industry peers.
In the last couple of years the Gross Margin of NPCE has remained more or less at the same level.
NPCE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y0.65%
NPCE Yearly Profit, Operating, Gross MarginsNPCE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

NPCE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NPCE has more shares outstanding
The number of shares outstanding for NPCE has been increased compared to 5 years ago.
Compared to 1 year ago, NPCE has a worse debt to assets ratio.
NPCE Yearly Shares OutstandingNPCE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
NPCE Yearly Total Debt VS Total AssetsNPCE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -4.00, we must say that NPCE is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.00, NPCE is doing worse than 65.08% of the companies in the same industry.
A Debt/Equity ratio of 7.43 is on the high side and indicates that NPCE has dependencies on debt financing.
NPCE has a Debt to Equity ratio of 7.43. This is amonst the worse of the industry: NPCE underperforms 88.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 7.43
Debt/FCF N/A
Altman-Z -4
ROIC/WACCN/A
WACC8.94%
NPCE Yearly LT Debt VS Equity VS FCFNPCE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

NPCE has a Current Ratio of 5.37. This indicates that NPCE is financially healthy and has no problem in meeting its short term obligations.
NPCE's Current ratio of 5.37 is fine compared to the rest of the industry. NPCE outperforms 79.37% of its industry peers.
NPCE has a Quick Ratio of 4.48. This indicates that NPCE is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of NPCE (4.48) is better than 76.72% of its industry peers.
Industry RankSector Rank
Current Ratio 5.37
Quick Ratio 4.48
NPCE Yearly Current Assets VS Current LiabilitesNPCE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.78% over the past year.
NPCE shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.14%.
NPCE shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.67% yearly.
EPS 1Y (TTM)25.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.74%
Revenue 1Y (TTM)22.14%
Revenue growth 3Y20.93%
Revenue growth 5Y16.67%
Sales Q2Q%19.18%

3.2 Future

NPCE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.37% yearly.
NPCE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.01% yearly.
EPS Next Y8.28%
EPS Next 2Y17.75%
EPS Next 3Y18.22%
EPS Next 5Y21.37%
Revenue Next Year17.66%
Revenue Next 2Y14.71%
Revenue Next 3Y18.37%
Revenue Next 5Y22.01%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NPCE Yearly Revenue VS EstimatesNPCE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
NPCE Yearly EPS VS EstimatesNPCE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NPCE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NPCE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NPCE Price Earnings VS Forward Price EarningsNPCE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NPCE Per share dataNPCE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

NPCE's earnings are expected to grow with 18.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.75%
EPS Next 3Y18.22%

More info and screens

0

5. Dividend

5.1 Amount

NPCE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROPACE INC

NASDAQ:NPCE (5/12/2025, 1:31:22 PM)

13.31

+0.42 (+3.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-04 2025-03-04/amc
Earnings (Next)05-13 2025-05-13/amc
Inst Owners58.03%
Inst Owner Change4.3%
Ins Owners4.05%
Ins Owner Change-89.82%
Market Cap435.90M
Analysts84.62
Price Target17.19 (29.15%)
Short Float %1.48%
Short Ratio1.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.7%
Min EPS beat(2)20.82%
Max EPS beat(2)30.58%
EPS beat(4)4
Avg EPS beat(4)17.22%
Min EPS beat(4)2.47%
Max EPS beat(4)30.58%
EPS beat(8)8
Avg EPS beat(8)20.79%
EPS beat(12)10
Avg EPS beat(12)14.06%
EPS beat(16)10
Avg EPS beat(16)-704.47%
Revenue beat(2)1
Avg Revenue beat(2)3.81%
Min Revenue beat(2)-0.6%
Max Revenue beat(2)8.22%
Revenue beat(4)3
Avg Revenue beat(4)3.37%
Min Revenue beat(4)-0.6%
Max Revenue beat(4)8.22%
Revenue beat(8)7
Avg Revenue beat(8)9.09%
Revenue beat(12)10
Avg Revenue beat(12)6.52%
Revenue beat(16)12
Avg Revenue beat(16)5.17%
PT rev (1m)-1.8%
PT rev (3m)3.51%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.78%
EPS NY rev (1m)-0.5%
EPS NY rev (3m)3.39%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.33%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.46
P/FCF N/A
P/OCF N/A
P/B 54.4
P/tB 54.4
EV/EBITDA N/A
EPS(TTM)-0.95
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS2.44
BVpS0.24
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.68%
ROE -338.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.94%
FCFM N/A
ROA(3y)-33.52%
ROA(5y)-34.1%
ROE(3y)-211.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.03%
GM growth 5Y0.65%
F-Score4
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity 7.43
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.3%
Cap/Sales 0.38%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.37
Quick Ratio 4.48
Altman-Z -4
F-Score4
WACC8.94%
ROIC/WACCN/A
Cap/Depr(3y)83.43%
Cap/Depr(5y)79.26%
Cap/Sales(3y)0.66%
Cap/Sales(5y)0.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.74%
EPS Next Y8.28%
EPS Next 2Y17.75%
EPS Next 3Y18.22%
EPS Next 5Y21.37%
Revenue 1Y (TTM)22.14%
Revenue growth 3Y20.93%
Revenue growth 5Y16.67%
Sales Q2Q%19.18%
Revenue Next Year17.66%
Revenue Next 2Y14.71%
Revenue Next 3Y18.37%
Revenue Next 5Y22.01%
EBIT growth 1Y20.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.73%
EBIT Next 3Y29.31%
EBIT Next 5YN/A
FCF growth 1Y8.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.89%
OCF growth 3YN/A
OCF growth 5YN/A